Skip to main content
OpenTrials
Completed

NCT Number: NCT04262284

Respreeza® Self-administration and Learning Program (AmAREtTI Study)

According to the Respreeza® Summary of Product Characteristics, the initial infusions must be administered under the supervision of a health professional experienced in the treatment of alpha-1 antitrypsin deficiency, although subsequent infusions may be administered at home by the person responsible for care or by the patient.

Clinical data on self-administration of Respreeza® are however limited and the grounds for self-administration are left to the assessment of the attending physician, who needs to ensure that appropriate training is delivered.

In this context, CSL Behring would like to run a clinical study in order to assess the effectiveness of a home self-administration learning program in terms of switching to self-administration, and the long term maintenance of this administration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alpha-1 Antitrypsin Deficiency Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Emphysema Genetic Diseases, Inborn Liver Diseases Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Subcutaneous Emphysema alpha 1-Antitrypsin Deficiency

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Angers, Angers, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (age ≥18 years old).
  • Patients suffering from AATD treated by Respreeza® through a peripheral vein at home for at least 3 month (consecutives or not). The 3-month period of treatment with Respreeza® does not necessarily correspond to the 3 months prior to inclusion.
  • Patient accompanied by a third person at home
  • Patients deemed to be suitable by the investigator for self-administration.
  • Patients with a life expectancy of over 3 years.
  • Patients who have been informed verbally and in writing via the information leaflet and who have signed the informed consent form.

Exclusion criteria

  • In order to reflect the reality of everyday practice, no non-inclusion criteria are intended except for patient refusal to take part in the study.

Treatment and study plan

Primary outcomes

  1. Percentage of patients who switch to self-administration without the presence of a nurse at the end of the learning program

    Time frame: Up to 8 weeks

    A patient will be permitted to switch to self-administration without the presence of a nurse if the following conditions are met:

    • Three consecutive successful self-administrations by the patient in the presence of the nurse but without assistance during the learning phase.
    • Validation of the learning grid The percentage is based on number of patient switching to self-administration and remains in self-administration 12 months after

  2. Percentage of patients who switch to self-administration without the presence of a nurse

    Time frame: Up to 12 months

Secondary outcomes

  1. Percentage of patients who switch to self-administration without the presence of a nurse

    Time frame: Up to 8 weeks

    A patient will be permitted to switch to self-administration without the presence of a nurse if the following conditions are met:

    • Three consecutive successful self-administrations by the patient in the presence of the nurse but without assistance during the learning phase.
    • Validation of the learning grid The percentage is based on number of patient switching to self-administration

  2. Patient characteristics

    Time frame: At inclusion

    Socio-demographic data, disease history, concomitant treatments, substitution protocol, percentage of theoretical forced expiratory volume at one second (FEV1), diffusing capacity of lung for carbon monoxide (DLCO), distance from home to hospital, type of follow-up (in hospital, in surgery)

  3. Degree of autonomy

    Time frame: At inclusion and 12 months after self-administration

    The change in the degree of autonomy will be defined as the difference between the autonomy assessed at 12 months and inclusion according to an EVA

  4. The time frame for autonomy

    Time frame: Up to 12 months

    The time to achieve autonomy will be defined by the time between the first learning session for self-administration and the first self-administration without nurse.

  5. Evolution of patients Quality of Life with Saint George's Respiratory Questionnaire (SGRQ)

    Time frame: Up to 12 months

  6. Patients satisfaction for treatment administration by a nurse and for self-administration

    Time frame: Up to 12 months

    Satisfaction for treatment administration by a nurse will be assessed at inclusion by visual analog scale (VAS) Satisfaction for self-administration will be assessed after 12 months after the 1st self-administration or in case of study withdrawal by VAS

  7. Satisfaction about learning program

    Time frame: Up to 8 weeks

    Satisfaction about learning program will be assessed at the end of the learning program by VAS

  8. Tolerance and safety

    Time frame: Up to 12 months

    General and local tolerance at the administration site assessed by the nature and number of adverse events (AEs) and immunoglobulin E impaired gas exchange (IGEs).

  9. Compliance/Observance

    Time frame: Up to 8 weeks

    Compliance/observance measured by the number of scheduled and unrealized sessions.

  10. Determining factors for switch to self-administration

    Time frame: Up to 8 weeks

    Determining factors that may be associated with the transition to self-administration (demographics, disease history, concomitant treatments, substitution protocol, FEV1, QoL at inclusion, duration of learning program).

Sponsors and collaborators

Lead sponsor

CSL Behring

Industry

Registry information

Official study title

Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage)

Acronym: AmAREtTI

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Feb 10, 2020
Registry last updated
May 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.